Tocilizumab IL-6 Response Probability Calculator

Estimate tocilizumab response probability in RA, giant cell arteritis, CRS, and COVID-19 based on IL-6 pathway biomarkers and clinical disease characteristics.

Weight
Height
Clinical Guidance

BMI is a screening measure of body size, not a direct measure of body fat. The standard WHO categories are underweight (<18.5), normal (18.5–24.9), overweight (25–29.9), and obese (≥30).

BMI can overestimate body fat in athletes with high muscle mass and underestimate it in older adults with low muscle mass. Interpret it alongside waist circumference and clinical context rather than as a standalone diagnosis.

⚕ Clinical Disclaimer: These calculators are for educational and reference purposes only. Always verify results with qualified clinical judgment and current clinical guidelines. Do not use as a sole basis for medical decisions.
Advertisement

How It Works

Estimate tocilizumab response probability in RA, giant cell arteritis, CRS, and COVID-19 based on IL-6 pathway biomarkers and clinical disease characteristics

Each component has a specific meaning:

  • IL-6 pathway biomarkers — The il-6 pathway biomarkers recorded for the scenario being assessed.
  • Clinical disease characteristics — The clinical disease characteristics recorded for the scenario being assessed.

Note: Interpret the tocilizumab il-6 response result against the thresholds and context described above.

How to Use

Enter the IL-6 pathway biomarkers, clinical disease characteristics for the scenario you are assessing. Estimate tocilizumab response probability in RA, giant cell arteritis, CRS, and COVID-19 based on IL-6 pathway biomarkers and clinical disease characteristics. Use the tocilizumab il-6 response result to inform your calculation.

Frequently Asked Questions